• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization.

作者信息

Schanda Julia, Lee Chun-Wei, Wohlan Katharina, Müller-Kuller Uta, Kunkel Hana, Coco Isabell Quagliano-Lo, Stein Stefan, Metz Alexander, Koch Joachim, Lausen Jörn, Platzbecker Uwe, Medyouf Hind, Gohlke Holger, Heuser Michael, Eder Matthias, Grez Manuel, Scherr Michaela, Wichmann Christian

机构信息

Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany.

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany.

出版信息

Haematologica. 2017 May;102(5):e170-e174. doi: 10.3324/haematol.2016.161570. Epub 2017 Feb 2.

DOI:10.3324/haematol.2016.161570
PMID:28154087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5685283/
Abstract
摘要

相似文献

1
Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization.通过一种小分子四聚化抑制剂抑制RUNX1/ETO致癌活性。
Haematologica. 2017 May;102(5):e170-e174. doi: 10.3324/haematol.2016.161570. Epub 2017 Feb 2.
2
The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells.在急性髓系白血病细胞中，t(8;21)融合蛋白RUNX1-ETO下调丙酮酸激酶M2（PKM2）。
Leuk Lymphoma. 2017 Aug;58(8):1985-1988. doi: 10.1080/10428194.2016.1272690. Epub 2017 Jan 16.
3
Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor.AML1-ETO 阳性白血病细胞中突变型 c-KIT 激酶的抑制恢复了对 PARP 抑制剂的敏感性。
Blood Adv. 2019 Dec 10;3(23):4050-4054. doi: 10.1182/bloodadvances.2019000756.
4
Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.RUNX1/ETO 融合蛋白模块驱动 CD34+ 人祖细胞扩增的兼容性。
Oncogene. 2019 Jan;38(2):261-272. doi: 10.1038/s41388-018-0441-7. Epub 2018 Aug 9.
5
Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.髓系易位基因 CBFA2T3 指导复发基因程序，并决定 AML 患者的具体结局。
Blood Adv. 2019 May 14;3(9):1379-1393. doi: 10.1182/bloodadvances.2018028514.
6
MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.MEIS2 是 AML1-ETO 阳性 AML 的致癌伙伴。
Cell Rep. 2016 Jul 12;16(2):498-507. doi: 10.1016/j.celrep.2016.05.094. Epub 2016 Jun 23.
7
RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins.RUNX 介导的生长停滞和衰老可被表达 RUNX1 融合癌蛋白的细胞中的多种机制削弱。
J Cell Biochem. 2018 Mar;119(3):2750-2762. doi: 10.1002/jcb.26443. Epub 2017 Nov 20.
8
Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.水杨酸盐、二氟尼柳及其代谢产物可抑制CBP/p300并具有抗癌活性。
Elife. 2016 May 31;5:e11156. doi: 10.7554/eLife.11156.
9
Destabilization of AETFC through C/EBPα-mediated repression of LYL1 contributes to t(8;21) leukemic cell differentiation.通过C/EBPα介导的LYL1抑制导致AETFC不稳定，这有助于t(8;21)白血病细胞分化。
Leukemia. 2019 Jul;33(7):1822-1827. doi: 10.1038/s41375-019-0398-8. Epub 2019 Feb 12.
10
ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.锌指蛋白36样蛋白2（ZFP36L2）是一种新的急性髓系白血病1（AML1）靶基因，可诱导急性髓系白血病（AML）细胞凋亡并抑制细胞增殖。
Leuk Res. 2018 May;68:15-21. doi: 10.1016/j.leukres.2018.02.017. Epub 2018 Feb 27.

引用本文的文献

1
Identification of non-charged 7.44 analogs interacting with the NHR2 domain of RUNX1-ETO with improved antiproliferative effect in RUNX-ETO positive cells.鉴定与RUNX1-ETO的NHR2结构域相互作用的不带电荷的7.44类似物，其在RUNX-ETO阳性细胞中具有增强的抗增殖作用。
Sci Rep. 2025 May 22;15(1):17720. doi: 10.1038/s41598-025-02422-z.
2
Biophysical and pharmacokinetic characterization of a small-molecule inhibitor of RUNX1/ETO tetramerization with anti-leukemic effects.具有抗白血病作用的 RUNX1/ETO 四聚体小分子抑制剂的物理化学和药代动力学特征。
Sci Rep. 2022 Aug 19;12(1):14158. doi: 10.1038/s41598-022-17913-6.
3
Modelling t(8;21) acute myeloid leukaemia - What have we learned?对t(8;21)急性髓系白血病的建模——我们学到了什么？
MedComm (2020). 2020 Sep 24;1(3):260-269. doi: 10.1002/mco2.30. eCollection 2020 Dec.
4
Transcription Factors, R-Loops and Deubiquitinating Enzymes: Emerging Targets in Myelodysplastic Syndromes and Acute Myeloid Leukemia.转录因子、R环与去泛素化酶：骨髓增生异常综合征和急性髓系白血病中的新兴靶点
Cancers (Basel). 2021 Jul 26;13(15):3753. doi: 10.3390/cancers13153753.
5
Gene Transcription as a Therapeutic Target in Leukemia.基因转录作为白血病的治疗靶点。
Int J Mol Sci. 2021 Jul 8;22(14):7340. doi: 10.3390/ijms22147340.
6
Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia.RUNX1 转录因子活性的降低：CBFA2T3 模拟肽的应用——用于 B 细胞前体急性淋巴细胞白血病。
J Hematol Oncol. 2021 Mar 20;14(1):47. doi: 10.1186/s13045-021-01051-z.
7
An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1.AML 伴 t(8;21)(q22;q22.1);RUNX1-RUNX1T1 的分子发病机制及潜在治疗靶点的研究进展。
Blood Adv. 2020 Jan 14;4(1):229-238. doi: 10.1182/bloodadvances.2019000168.
8
Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention.小儿急性髓系白血病（AML）：从基因到模型迈向靶向治疗干预
Front Pediatr. 2019 Oct 15;7:401. doi: 10.3389/fped.2019.00401. eCollection 2019.

本文引用的文献

1
From determinants of RUNX1/ETO tetramerization to small-molecule protein-protein interaction inhibitors targeting acute myeloid leukemia.从 RUNX1/ETO 四聚体形成的决定因素到针对急性髓系白血病的小分子蛋白-蛋白相互作用抑制剂。
J Chem Inf Model. 2013 Sep 23;53(9):2197-202. doi: 10.1021/ci400332e. Epub 2013 Sep 12.
2
A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.由寡聚 AML1-ETO 引发的稳定转录因子复合物控制白血病发生。
Nature. 2013 Aug 1;500(7460):93-7. doi: 10.1038/nature12287. Epub 2013 Jun 30.
3
From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules.从计算机模拟发现到细胞内活性：用小分子靶向JNK蛋白相互作用
ACS Med Chem Lett. 2012 Aug 6;3(9):721-725. doi: 10.1021/ml300129b.
4
Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein.冬凌草甲素通过靶向 AML1-ETO 抑制 t(8;21) 白血病的发生，产生一种肿瘤抑制样蛋白。
Sci Transl Med. 2012 Mar 28;4(127):127ra38. doi: 10.1126/scitranslmed.3003562.
5
Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.二聚体-四聚体转变控制 RUNX1/ETO 白血病发病机制。
Blood. 2010 Jul 29;116(4):603-13. doi: 10.1182/blood-2009-10-248047. Epub 2010 Apr 29.
6
AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.AML1/ETO癌蛋白被导向AML1结合区域，并与其靶点上的AML1和HEB共定位。
PLoS Genet. 2008 Nov;4(11):e1000275. doi: 10.1371/journal.pgen.1000275. Epub 2008 Nov 28.
7
c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression.c-Jun氨基末端激酶介导AML1-ETO蛋白诱导的连接蛋白43表达。
Biochem Biophys Res Commun. 2007 May 4;356(2):505-11. doi: 10.1016/j.bbrc.2007.03.009. Epub 2007 Mar 8.
8
Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.靶向ETO的寡聚化结构域可干扰t(8;21)阳性白血病细胞中RUNX1/ETO的致癌活性。
Cancer Res. 2007 Mar 1;67(5):2280-9. doi: 10.1158/0008-5472.CAN-06-3360.
9
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.一种先前未被识别的t(8;21)转录本的可变剪接异构体促进白血病发生。
Nat Med. 2006 Aug;12(8):945-9. doi: 10.1038/nm1443. Epub 2006 Jul 30.
10
The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.神经同源二结构域（NHR2）的四聚体结构对AML1/ETO的活性至关重要。
Cancer Cell. 2006 Apr;9(4):249-60. doi: 10.1016/j.ccr.2006.03.012.